Estimating the hidden magnitude of the malaria community burden by Ketema, Tsige & Bassat Orellana, Quique
Comment
www.thelancet.com/infection   Published online April 8, 2020   https://doi.org/10.1016/S1473-3099(20)30142-0 1
Estimating the hidden magnitude of the malaria community 
burden
The second push for global malaria eradication, launched 
more than a decade ago,1 has motivated a renewed 
interest in the understanding of malaria transmission, 
and in the strategies required to interrupt it. In this 
respect, in order to eliminate malaria from a given 
geographical area, rapid detection and treatment of 
the clinical cases is rarely sufficient. In settings where 
transmission intensity is sufficiently high, popu­
lations exposed to continuous infective mosquito bites 
progressively develop a tolerance to malaria infections 
during the first few years of their life. This tolerance 
protects them against malaria disease, but not necessarily 
against the infection itself. This situation results in a 
varying frequency of asymptomatic carriage of malaria 
parasites. Indeed, the higher the transmission intensity, 
the earlier the acquisition of immunity and the larger 
the population capable of carrying malaria parasites 
in their blood without necessarily expressing clinical 
symptoms. To paraphrase the “iceberg” metaphor, some 
authors have described that the true burden of malaria 
infections lies “hidden beneath the surface”, and that 
clinical cases would only represent the so­called “ears of 
the hippopotamus”2 of the total malaria burden. These 
symptomless infections, not motivating an active search 
for treatment, are invisible to the system, although 
they remain potentially transmissible to mosquitoes, 
thus acting as silent reservoirs of transmission.3 For this 
reason, estimating the true burden of malaria infections 
from the relatively small proportion of those that are 
clinically visible and detectable through the health system 
can provide an actionable idea of the magnitude of 
undercounting, and therefore of the efforts required to 
interrupt malaria transmission at the community level.
In The Lancet Infectious Diseases, Gillian Stresman and 
colleagues,4 representing a variety of malaria­endemic 
countries, propose a new approach to quantify, using 
a Bayesian model, the proportion of the total malaria 
infections in a given community detected through 
routine passive case surveillance. Such an indicator, 
termed P(Detect) and ranging from 0 to 100%, would 
use health system clinical data to derive an idea of the 
overall community transmission, by expressing the 
probability that an infection becomes symptomatic 
and potentially detected by the health system. Thus, 
theoretically, a very high value of P(Detect)—ie, a 
value approaching 100%—would suggest that the 
vast majority of infections are clinically manifest and 
therefore detectable by the health system, whereas 
a low value would indicate that most of the parasite 
reservoir remains undetected by the health system. 
As the authors suggest, and for elimination purposes, 
such an indicator could have an enormous potential to 
help to identify “the critical point at which programmes 
could scale back control activities and rely on the health 
system to identify all infections”.4 
The pooled analysis of paired health facility 
(passive case detection) and community survey data 
(household surveys) allows the study authors to explore 
the association between infection detection and 
transmission in malaria endemic areas. The analysis of 
such an impressive dataset (including 471 clusters in 
13 countries for Plasmodium falciparum and 231 clusters 
in seven countries for Plasmodium vivax, for the period 
2008–2017) shows low median estimated P(Detect) 
values (12·5% for P falciparum and 10·1% for P vivax). 
However, their more important finding is a negative 
association between the level of infection detection 
and the underlying intensity of transmission for 
both species (P falciparum adjusted odds ratio 0·63 
[95% CI 0·57–0·69] and P vivax adjusted odds ratio 0·52 
[0·47–0·57]). 
As a plausible explanation for these findings, the 
authors suggest that as disease transmission and 
repeated exposure to malaria infection decrease, 
population immunity to this deadly infection will start 
to wane, rendering the population vulnerable again and 
gradually non­immune.5 As a result, the proportion of 
the infections that will become clinical (and as such, for 
which the affected individuals might seek health care 
and thus are detectable at the health system level) will 
also increase. Subgroup analyses done by the authors 
exploring the variability of P(Detect) according to age 
or seasonality further substantiate this hypothesis 
and  help to validate  their results, although such an 
association in the case of P vivax was less conclusive. 
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presented relates to the absence of data in their analyses 
from highly malaria­endemic areas in the Pacific (eg, 
Papua­Indonesia and Papua New Guinea), where 
P vivax is a major cause of infection and disease, and 
where immunity to this species builds up even faster 
than it does for P falciparum.6,7 Generating estimates 
of P(Detect) in those regions could have further 
illustrated the association between transmission and 
clinical disease for a malaria species that clearly has its 
own particularities, and is extremely relevant if global 
eradication of malaria is to be achieved.
Despite the aforementioned limitations, the authors 
should be praised for their proposed approach to 
quantifying the degree of hidden malaria transmission, 
which is an important indicator of the likelihood of 
success of all malaria control and elimination strategies 
worldwide. 
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